283 related articles for article (PubMed ID: 18389263)
1. Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson's disease. Variability in familial Parkinson's disease.
Markopoulou K; Dickson DW; McComb RD; Wszolek ZK; Katechalidou L; Avery L; Stansbury MS; Chase BA
Acta Neuropathol; 2008 Jul; 116(1):25-35. PubMed ID: 18389263
[TBL] [Abstract][Full Text] [Related]
2. Pathological findings in a patient with alpha-synuclein p.A53T and familial Parkinson's disease.
Nishioka K; Hashizume Y; Takanashi M; Daida K; Li Y; Yoshino H; Tambasco N; Prontera P; Hattori Y; Ueda A; Watanabe H; Hattori N
Parkinsonism Relat Disord; 2020 Dec; 81():183-187. PubMed ID: 33171430
[TBL] [Abstract][Full Text] [Related]
3. Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation.
Kiely AP; Ling H; Asi YT; Kara E; Proukakis C; Schapira AH; Morris HR; Roberts HC; Lubbe S; Limousin P; Lewis PA; Lees AJ; Quinn N; Hardy J; Love S; Revesz T; Houlden H; Holton JL
Mol Neurodegener; 2015 Aug; 10():41. PubMed ID: 26306801
[TBL] [Abstract][Full Text] [Related]
4. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
[TBL] [Abstract][Full Text] [Related]
5. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.
Lo Bianco C; Schneider BL; Bauer M; Sajadi A; Brice A; Iwatsubo T; Aebischer P
Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17510-5. PubMed ID: 15576511
[TBL] [Abstract][Full Text] [Related]
6. Inclusion body formation and neurodegeneration are parkin independent in a mouse model of alpha-synucleinopathy.
von Coelln R; Thomas B; Andrabi SA; Lim KL; Savitt JM; Saffary R; Stirling W; Bruno K; Hess EJ; Lee MK; Dawson VL; Dawson TM
J Neurosci; 2006 Apr; 26(14):3685-96. PubMed ID: 16597723
[TBL] [Abstract][Full Text] [Related]
7. [Pathology of familial Parkinson's disease].
Wakabayashi K; Takahashi H
Brain Nerve; 2007 Aug; 59(8):851-64. PubMed ID: 17713121
[TBL] [Abstract][Full Text] [Related]
8. α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy?
Kiely AP; Asi YT; Kara E; Limousin P; Ling H; Lewis P; Proukakis C; Quinn N; Lees AJ; Hardy J; Revesz T; Houlden H; Holton JL
Acta Neuropathol; 2013 May; 125(5):753-69. PubMed ID: 23404372
[TBL] [Abstract][Full Text] [Related]
9. The regulatory role of α-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson's disease.
Yasuda T; Mochizuki H
Apoptosis; 2010 Nov; 15(11):1312-21. PubMed ID: 20221696
[TBL] [Abstract][Full Text] [Related]
10. Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study.
Wilson H; Dervenoulas G; Pagano G; Koros C; Yousaf T; Picillo M; Polychronis S; Simitsi A; Giordano B; Chappell Z; Corcoran B; Stamelou M; Gunn RN; Pellecchia MT; Rabiner EA; Barone P; Stefanis L; Politis M
Lancet Neurol; 2019 Aug; 18(8):748-759. PubMed ID: 31229470
[TBL] [Abstract][Full Text] [Related]
11. Novel α-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology.
Pasanen P; Myllykangas L; Siitonen M; Raunio A; Kaakkola S; Lyytinen J; Tienari PJ; Pöyhönen M; Paetau A
Neurobiol Aging; 2014 Sep; 35(9):2180.e1-5. PubMed ID: 24746362
[TBL] [Abstract][Full Text] [Related]
12. α-synuclein expression from a single copy transgene increases sensitivity to stress and accelerates neuronal loss in genetic models of Parkinson's disease.
Cooper JF; Spielbauer KK; Senchuk MM; Nadarajan S; Colaiácovo MP; Van Raamsdonk JM
Exp Neurol; 2018 Dec; 310():58-69. PubMed ID: 30194957
[TBL] [Abstract][Full Text] [Related]
13. Genetic assessment of familial and early-onset Parkinson's disease in a Greek population.
Bozi M; Papadimitriou D; Antonellou R; Moraitou M; Maniati M; Vassilatis DK; Papageorgiou SG; Leonardos A; Tagaris G; Malamis G; Theofilopoulos D; Kamakari S; Stamboulis E; Hadjigeorgiou GM; Athanassiadou A; Michelakakis H; Papadimitriou A; Gasser T; Stefanis L
Eur J Neurol; 2014 Jul; 21(7):963-8. PubMed ID: 24313877
[TBL] [Abstract][Full Text] [Related]
14. Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson's disease.
Paumier KL; Sukoff Rizzo SJ; Berger Z; Chen Y; Gonzales C; Kaftan E; Li L; Lotarski S; Monaghan M; Shen W; Stolyar P; Vasilyev D; Zaleska M; D Hirst W; Dunlop J
PLoS One; 2013; 8(8):e70274. PubMed ID: 23936403
[TBL] [Abstract][Full Text] [Related]
15. Interaction between Parkin and
Madsen DA; Schmidt SI; Blaabjerg M; Meyer M
Cells; 2021 Jan; 10(2):. PubMed ID: 33572534
[TBL] [Abstract][Full Text] [Related]
16. Importance of familial Parkinson's disease and parkinsonism to the understanding of nigral degeneration in sporadic Parkinson's disease.
Hattori N; Shimura H; Kubo S; Wang M; Shimizu N; Tanaka K; Mizuno Y
J Neural Transm Suppl; 2000; (60):101-16. PubMed ID: 11205133
[TBL] [Abstract][Full Text] [Related]
17. Parkin depletion delays motor decline dose-dependently without overtly affecting neuropathology in α-synuclein transgenic mice.
Fournier M; Roux A; Garrigue J; Muriel MP; Blanche P; Lashuel HA; Anderson JP; Barbour R; Huang J; du Montcel ST; Brice A; Corti O
BMC Neurosci; 2013 Nov; 14():135. PubMed ID: 24192137
[TBL] [Abstract][Full Text] [Related]
18. Analysis of LRRK2, SNCA, Parkin, PINK1, and DJ-1 in Zambian patients with Parkinson's disease.
Yonova-Doing E; Atadzhanov M; Quadri M; Kelly P; Shawa N; Musonda ST; Simons EJ; Breedveld GJ; Oostra BA; Bonifati V
Parkinsonism Relat Disord; 2012 Jun; 18(5):567-71. PubMed ID: 22445250
[TBL] [Abstract][Full Text] [Related]
19. Parkinson's disease with Lewy bodies associated with a heterozygous PARKIN dosage mutation.
Sharp ME; Marder KS; Côté L; Clark LN; Nichols WC; Vonsattel JP; Alcalay RN
Mov Disord; 2014 Apr; 29(4):566-8. PubMed ID: 24375549
[TBL] [Abstract][Full Text] [Related]
20. CRISPR-Cas9 Gene Editing Protects from the A53T-SNCA Overexpression-Induced Pathology of Parkinson's Disease
Yoon HH; Ye S; Lim S; Jo A; Lee H; Hong F; Lee SE; Oh SJ; Kim NR; Kim K; Kim BJ; Kim H; Lee CJ; Nam MH; Hur JW; Jeon SR
CRISPR J; 2022 Feb; 5(1):95-108. PubMed ID: 35191750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
